Invitation to Alligator Bioscience's Earnings Call on 26 August 2026

About this update from Alligator Bioscience Ab

LUND, SE / ACCESS Newswire / August 20, 2026 / Alligator Bioscience (STO:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for April - June 2026 on Wednesday, 26 August 2026, at 8:00 a.m. CEST. On the same day, Alligator will host a webinar and conference call for investors, analysts and media at 3:00 p.m. CEST / 9:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session. The call will be held in English. Attendees are required to register in advance via this link and are welcome to submit questions in advance to [email protected]. The full report will be available upon publication on Alligator's website . For further information, please contact: Søren Bregenholt, CEO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact persons set out above, at 8:45 a.m. CEST on 20 August 2026. About Alligator Bioscience Alligator is a biotechnology company that has historically focused on tumor-directed immuno-oncology. Following a strategic refocus, Alligator is prioritizing the value of its economic interest in HLX22, an anti-HER2 monoclonal antibody being developed by Shanghai Henlius Biotech Inc., from which Alligator is entitled to a share of revenues without incurring development costs. Alligator has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset in the near term. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments Invitation to Alligator Bioscience's earnings call on 26 August 2026 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

View stock analysis, news, and events for Alligator Bioscience Ab